Acido folico e folati prima di una gravidanza

EUROCAT Joint Action (2011-2013)

EUROCAT Joint Action 2011-2013

The EUROCAT (European Network for surveillance of Congenital Anomalies) Joint Action (JA), funded by the Public Health Programme 2008-2013 of the European Commission started on January 1st 2011 .

This JA combines funding of the EU and Member States (MS) in order to secure a sustainable, high quality and easily accessible information system on Congenital Anomalies (CA) for almost one third of the European birth population. The results are expected to have an important impact on future member state policy on rare diseases.

EUROCAT JA has among its main goals the improvement of surveillance and the identification of strategies for primary prevention of CA.
It encompasses 36 Associate Partners, 9 Collaborating Partners and is structured into 9 Work Packages (WP). The structure and principal expected outcomes can be viewed in the promotional leaflet (Link).

The National Centre for Rare Diseases (Istituto Superiore di Sanità) coordinates the Work Package 7 (WP7) that is focused on the effectiveness of CA primary prevention. A focus will be folic acid but this objective will also assess other potential routes including management of chronic diseases, drugs in pregnancy, maternal infection and vaccination, environmental pollution, alcohol and smoking, and other maternal lifestyle issues. WP7 will assess the feasibility and process for considering risk factors for CA in national plans of EU - MS for rare diseases, with support of EUROPLAN.

The WP7 final purpose is to elaborate, a set of evidence-based recommendations for the primary prevention of congenital anomalies to be included in European countries national plans/strategies

Documenti relativi